FOR IMMEDIATE RELEASE
Wednesday, July 9, 2003
Floyd E. Bloom, M.D.
Founding Chief Executive Officer
Neurome Announces Research Collaboration
with La Jolla Pharmaceutical Company
Collaboration to Pursue Investigation
of CNS Effects Often Found in Patients with Lupus
LA JOLLA, CA - Neurome, Inc. announced today it has established
a research collaboration with La Jolla Pharmaceutical Company
(Nasdaq: LJPC). The collaboration, which will focus on the
investigation of proteins in the brain that selectively bind
antibodies to double-stranded DNA found in patients with systemic
lupus erythematosus (lupus), combines Neurome's proprietary
technologies with La Jolla Pharmaceutical Company's experience
in discovering and developing innovative therapeutics to treat
the underlying causes of antibody-mediated diseases. This
agreement represents the parties' first collaboration together.
The collaboration will leverage Neurome's extensive experience
in Central Nervous System (CNS) diseases and proprietary technologies
(the Neurome Technologies) to provide La Jolla with information
on the potential targets in the Central Nervous System (CNS)
affected by the autoimmune disorder called lupus. Financial
terms were not disclosed.
"The Central Nervous System complications associated
with lupus can be very debilitating, yet we do not know what
causes them. Neurome is pleased to enter into a collaboration
with La Jolla directed at this important, yet poorly understood,
neurological syndrome," said Floyd E. Bloom, M.D., Founding
CEO and Chairman of the Board of Neurome and Chairman of the
Department of Neuropharmacology at The Scripps Research Institute.
"The combination of neuroscience expertise and cutting-edge
technologies make Neurome an excellent partner for this project,"
commented Matthew D. Linnik, Ph.D., Chief Scientific Officer
and Executive Vice President, Research at La Jolla Pharmaceutical
Company. "We are delighted to be working with Neurome
to uncover more details about the potential role of antibodies
in the CNS manifestations of lupus."
Warren G. Young, Ph.D., President and Chief Technology Officer
at Neurome added, "Neurome possesses unique technologies
for visualizing and measuring subtle changes in the Central
Nervous System. These sensitive methods have revealed subtle
shifts in gene expression patterns in other neuropathologies,
such as Alzheimer's disease. This collaboration with La Jolla
Pharmaceutical Company extends the application of the Neurome
Technologies to research on another devastating illness: lupus.
I believe the medical expertise at La Jolla and the research
tools at Neurome are a perfect match on the road to developing
effective therapeutic interventions."
Lupus is an autoimmune disease in which the body harms its
own healthy cells and tissues, leading to inflammation and
damage of various body tissues. A complex disease whose cause
is unknown, lupus can affect many parts of the body, including
the joints, kidneys, heart, lungs and central nervous system.
When the disease affects the brain and central nervous system,
it may result in headaches, dizziness, memory disturbances,
vision problems, seizures, stroke and changes in behavior.
There is no known cure for lupus, which is currently estimated
by the Lupus Foundation of America to affect at least 1.4
million Americans. Lupus occurs ten to 15 times more frequently
among adult females than among adult males.
Neurome, Inc., develops standardized, quantitative databases
that accurately depict and integrate gene expression patterns
in the three-dimensional context of the brain's structures,
circuits, and cells, and deploys these databases in primary
research directed toward the discovery and development of
gene targets for enhancement of brain function and treatment
of brain-based disease. Neurome performs contract brain research
for pharmaceutical and biotechnology companies while at the
same time pursuing its own in-house and collaborative research
protocols. The data collected from these efforts will populate
an evolving, comprehensive database available by subscription
and useful on a broad level for analyses of mouse models of
brain function and disease. In this regard, the application
of the Neurome Technologies will provide rigorous, quantitative
data that are optimally suited to the measurement of subtle
cell-type specific shifts in gene expression, as well as progression
and prevention of degenerative events affecting specific cell
classes and brain regions.
Except for historical statements, this press release contains
forward-looking statements involving significant risks and
uncertainties, and a number of factors, both foreseen and
unforeseen, could cause actual results to differ materially
from Neurome's current expectations. Forward-looking statements
include those which express a plan, belief, expectation, estimation,
anticipation, intent, contingency, future development or similar
expression. Readers are cautioned that forward-looking statements
are not guarantees of future performance and that undue reliance
should not be placed on such statements. Forward-looking statements
speak only as of the dates on which they were made. Neurome
undertakes no obligation to publicly update or revise any
forward-looking statements or to make any other forward-looking
statements, whether as a result of new information, future
events or otherwise unless required to do so by the securities
For more information, please contact Neurome, Inc., 11149
North Torrey Pines Road, La Jolla, California 92037-1031.
Telephone: (858) 677-0466; Fax (858) 677-0458; Web site: www.neurome.com.